NextGen Sciences Announces Commercial Alliance with Paragon Bioservices

NextGen Sciences Announces Commercial Alliance with Paragon Bioservices

NextGen Sciences, a wholly owned subsidiary of NextGen Group plc, the AIM-listed company, and a leading provider of gene-to-protein products and services, has announced a Commercial Alliance with Paragon Bioservices, Inc., (Baltimore, MD) a leading provider of contract research and manufacturing services in support of developing biologics. The Alliance expands the portfolio of both companies with the ability to offer existing and future customers an integrated offering including molecular biology, protein production, proteomics, functional assay development, biomarker discovery and monitoring.

This alliance extends NextGen Sciences’ commitment to expand their fee for service offering in strategic partnerships in addition to adding new capabilities in house such as the protein biomarker monitoring services which was announced in November 2007. NextGen Sciences and Paragon Bioservices have agreed to co-market each others fee for service offerings to the market which now allows client companies to choose a one stop shop for their entire gene to protein needs.

Commenting on the Alliance, Dr Mike Pisano, CEO of NextGen Sciences, said: “We are delighted to be able to work more formally with the team at Paragon. I have known them for over the past five years and respect their excellent service record in the industry. They have great credibility in the market and together with the unique capabilities of NextGen Sciences, we believe that we have the broadest and most exciting range of products and services available in the gene to protein arena to take to our existing and potential new customers. Already the customers of both companies are telling us that this is an exciting opportunity for them and look forward to working with the new alliance.”

“We are very excited about the Alliance with NextGen Sciences. Their instrumentation and software in the molecular biology area and their expertise in protein biomarker discovery and monitoring fits around our protein production and functional assay services very nicely”, commented Dr Marco Chacon, CEO of Paragon Bioservices. “Working with NextGen Sciences gives our customers a broad range of services to access from a single point of contact whether you have been a customer of NextGen Sciences or Paragon Bioservices in the past”

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.